






  





















































<!DOCTYPE html>
<html xmlns="https://www.w3.org/1999/xhtml" lang='en'>
<head>  
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="content-type" content="text/html; charset=UTF-8" />
    <meta name="robots" content="noindex,nofollow"/>
    <meta name="referrer" content="origin-when-cross-origin"/>
  <title>Remission in Subjects With Crohn&apos;s Disease, Open Label Extension - Tabular View - ClinicalTrials.gov</title>
    <link href="/ct2/show/record/NCT01070303" rel="canonical"/>
  
  <link rel="shortcut icon" href="/ct2/html/images/favicon.ico" />
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-144x144.png' sizes='144x144'>
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-114x114.png' sizes='114x114'>
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-72x72.png'   sizes='72x72'>
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-precomposed.png' >
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon.png' >

  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/jquery/css/superfish.css" media="screen" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/jquery/css/superfish-vertical.css" media="screen" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/css/base.css?v=b4" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/css/print.css" media="print" />
  <link rel="stylesheet" href="/ct2/html/ct3/css/w3-ct.css" type="text/css" />
  <!--[if lt IE 9]>
	<link rel="stylesheet" href="/ct2/html/ct3/css/w3-ct-oldIE.css" type="text/css" />
  <![endif]-->
  	

     <!--[if lte IE 7]>
           <link href="/ct2/html/ct3/css/target-IE7-and-below.css" rel="stylesheet" type="text/css">
    <![endif]-->

<link href="/ct2/html/ct3/css/trial-record.css?v=b4" rel="stylesheet" type="text/css" />
<link href="/ct2/html/ct3/css/ct2Header.css" rel="stylesheet" type="text/css" />


	<script type="text/javascript" src="/ct2/html/ct3/jquery/js/jquery.min.js?v=1.12.4"></script><noscript></noscript>
	    <script type="text/javascript" src="/ct2/html/ct3/jquery/js/superclick.js"></script><noscript></noscript>
    <script type="text/javascript" src="/ct2/html/ct3/jquery/js/jquery.cookie.js"></script><noscript></noscript>
    <script type="text/javascript" src="/ct2/html/images/frame/ct.js"></script><noscript></noscript>
    <script type="text/javascript" src="/ct2/html/ct3/js/ctmenu.js?v=b4"></script><noscript></noscript>

    <script type="text/javascript" src="/ct2/html/images/foresee/foresee-trigger.js"></script><noscript></noscript>
<script type="text/javascript">
    $(window).load(function(){
        loadCTCommon();
        });
</script>
 


  <script type="text/javascript">
    ncbi_pingWithImage=true;
    __ncbi_stat_url="//www.ncbi.nlm.nih.gov/stat";        
  </script>
  
  <meta name="ncbi_sid" content="861650e6985fe386_9165dSID"/>
  <meta name="ncbi_app" content="ctgov"/>
  <meta name="ncbi_db" content="ctgov"/>
  <meta name="ncbi_pdid" content="show_record"/>
  <meta name="ncbi_pcid" content="NCT01070303"/>
  <meta name="ncbi_ctreqid" content="RRe02V0c"/>
  <meta name="ncbi_ctsessid" content="SRe01h6U"/>
  <meta name="ncbi_ctipid" content="IzOkI5NS"/>
  <meta name="ncbi_cthost" content="wp2"/>
</head>

<body class="js one-column"> 
<div id="skip"> <a href="#main-content">Skip to Main Content</a> </div>

<script type="text/javascript">
	var RetractableBannerStateProperty = 'CT_NewsBannerState';
	
	ToggleBanner = function()
    {
        var theAccordion = $('#retractableBanner'); 
       	if (theAccordion.css("display") == "none") {
        		$('#showMore').css('visibility', 'hidden');
        	} else {
         		$('#showMore').css('visibility', 'visible');
        	}
        theAccordion.slideToggle({
            duration: 'fast',
            start: function(){
				            	if (typeof FuncReAlign !== 'undefined') {
            		$( "table.fixedHeader-floating" ).hide();
            	}
			},
            done: function(){
            	if (theAccordion.css("display") == "none") {
            		rememberRetractableBannerState('hide');
            	} else {
            		rememberRetractableBannerState('show');
            	}
            	if (typeof FuncReAlign !== 'undefined') {
                	FuncReAlign();  
            		$( "table.fixedHeader-floating" ).show();
            	}
            }
		});
    };
	    
	var rememberRetractableBannerState = function(newState) {
		try {
			sessionStorage.setItem(RetractableBannerStateProperty, newState);
		} catch (e) {}
	};

	$(window).ready(function(){
		try {
			var retractableBannerState = sessionStorage.getItem(RetractableBannerStateProperty);
					    if (retractableBannerState === null  || retractableBannerState === 'show') {
				ToggleBanner();
			}
		} catch (e) {};
	});
</script><noscript></noscript>
<div class="w3-container w3-center" style="padding:1.5ex 0.125in 0;background:#205493;color:white">
	<div style="font-weight:bold;">This site became the new ClinicalTrials.gov on June 19th. <a href="https://www.nlm.nih.gov/pubs/techbull/mj17/mj17_clinicaltrials_improve_usability.html" style="margin-left:1em;color:white;border-bottom-color:white;">Learn more.</a>
		<div id="showMore" style="float:right;cursor:pointer;border-bottom:1px dotted white;" onclick="ToggleBanner();">Show more <img src="/ct2/html/ct3/images/show-more.png" style="width:17px;"></div>
	</div>
	<div id="retractableBanner" style="margin-top:1ex;display:none;">We will be updating this site in phases. This allows us to move faster and to deliver better services.
		<div id="showLess" style="float:right;cursor:pointer;border-bottom:1px dotted white;" onclick="ToggleBanner();">Show less <img src="/ct2/html/ct3/images/show-less.png" style="width:17px;"></div>
	</div>
</div>
<div id="wrapper" style="padding-top:0;">  <div id="longAlert" class="w3-hide-small" style="background-color:papayawhip;font-size:small;margin-bottom:1.5ex;">
	<img src="/ct2/html/ct3/images/warning.png" alt="ClinicalTrials.gov Menu" style="max-width:0.8rem;cursor:pointer;"/>
    <b>IMPORTANT</b>: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study.  <a href="/ct2/about-site/disclaimer">Read more...</a>
</div>
<div id="shortAlert" class="w3-hide-medium w3-hide-large" style="background-color:papayawhip;font-size:small;margin-bottom:1.5ex;">
	<img src="/ct2/html/ct3/images/warning.png" alt="ClinicalTrials.gov Menu" style="max-width:0.8rem;cursor:pointer;"/>
    <b>IMPORTANT</b>: Talk with a trusted healthcare professional before volunteering for a study. <a href="/ct2/about-site/disclaimer">Read more...</a>
</div>

  
	<div id="header" style="float:left;"> <a href="/ct2/home" style="border-style:none;box-shadow:none;"><img src='/ct2/html/ct3/images/ct.gov-logo.png' alt='ClinicalTrials.gov' style='max-width:100%;' /></a><br />
    	<div id="tagline">A service of the U.S. National Institutes of Health</div>
  	</div>
					<div id="hamburger" class="w3-hide-medium w3-hide-large" style="float:right;border-width:0;display:block;margin-left:1em;padding:4px;"
			title="Show menus">
			<img src="/ct2/html/ct3/images/hamburgerMenuIcon.png" alt="ClinicalTrials.gov Menu" style="max-width:30px;cursor:pointer;" 
			 onclick="$('#global-nav-popupMenu').toggle();"/>
		</div>
		<div id="global-nav-popupMenu" class="w3-hide-medium w3-hide-large w3-modal w3-center" 
			 style="display:none;" onclick="$('#global-nav-popupMenu').hide();"> 			<div id="global-nav-popupMenu-content" class="w3-modal-content">
				<div class="w3-container">
				    <span onclick="$('#global-nav-popupMenu').hide();"
				      class="w3-closebtn">&times;</span>
					<ul class="sf-menu sf-vertical">
									<li class="first"><a href="/ct2/search/index">Find Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Find Studies Menu"></a>
			<ul>
                      <li                  ><a                  href="/ct2/home">New Search</a></li>
                      <li                  ><a         href="/ct2/search/advanced">Advanced Search</a></li>
                      <li                  ><a     href="/ct2/search/browse?brwse=cond_cat">See Studies by Topic</a></li>
                      <li                  ><a             href="/ct2/search/map">See Studies on Map</a></li>
                      <li class="new-group"><a           href="/ct2/help/how-find/index">How to Search</a></li>
                      <li                  ><a href="/ct2/help/how-use-search-results">How to Use Search Results</a></li>
                      <li                  ><a        href="/ct2/help/how-find/find-study-results">How to Find Results of Studies</a></li>
                      <li                  ><a          href="/ct2/help/how-read-study">How to Read a Study Record</a></li>
			</ul>
			</li>
			<li><a href="/ct2/about-studies">About Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="About Studies Menu"></a>
			<ul>
                      <li><a href="/ct2/about-studies/learn">Learn About Studies</a></li>
                      <li><a  href="/ct2/about-studies/other-sites">Other Sites About Studies</a></li>
                      <li><a         href="/ct2/about-studies/glossary">Glossary of Common Site Terms</a></li>
			</ul>
			</li>
			<li><a href="/ct2/manage-recs">Submit Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Submit Studies Menu"></a>
			<ul>
                      <li><a                          href="/ct2/manage-recs/background">Why Should I Register and Submit Results?</a></li>
                      <li><a                                href="/ct2/manage-recs/fdaaa">FDAAA 801 Requirements</a></li>
                      <li class="new-group"><a    href="/ct2/manage-recs/how-apply">How to Apply for an Account</a></li>
                      <li><a                        href="/ct2/manage-recs/how-register">How to Register Your Study</a></li>
                      <li><a                         href="/ct2/manage-recs/how-edit">How to Edit Your Study Record</a></li>
                      <li><a                   href="/ct2/manage-recs/how-report">How to Submit Your Results</a></li>
                      <li class="new-group"><a       href="/ct2/manage-recs/faq">Frequently Asked Questions</a></li>
                      <li                  ><a href="/ct2/manage-recs/resources">Support Materials</a></li>
                      <li                  ><a      href="/ct2/manage-recs/present">Training Materials</a></li>
			</ul>
			</li>
			<li><a href="/ct2/resources">Resources<img src="/ct2/html/ct3/images/pulldown.png" alt="Resources Menu"></a>
			<ul>
                      <li                  ><a    href="/ct2/resources/pubs">Selected Publications</a></li>
                      <li                  ><a       href="/ct2/resources/alert">Clinical Alerts and Advisories</a></li>
                      <li                  ><a     href="/ct2/resources/rss">RSS Feeds</a></li>
                      <li class="new-group"><a href="/ct2/resources/trends">Trends, Charts, and Maps</a></li>
                      <li                  ><a   href="/ct2/resources/download">Downloading Content for Analysis</a></li>
			</ul>
			</li>
			<li class="last"><a href="/ct2/about-site">About Site<img src="/ct2/html/ct3/images/pulldown.png" alt="About Site Menu"></a>
			<ul>
                      <li class="new-group"><a href="/ct2/about-site/background">ClinicalTrials.gov Background</a></li>
                      <li                  ><a    href="/ct2/about-site/results">About the Results Database</a></li>
                      <li                  ><a    href="/ct2/about-site/history">History, Policies, and Laws</a></li>
                      <li                  ><a   href="/ct2/about-site/for-media">Media/Press Resources</a></li>
                      <li class="new-group"><a          href="/ct2/about-site/link-to">Linking to This Site</a></li>
                      <li                  ><a           href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
                      <li                  ><a      href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			</ul>
			</li>
					</ul>
				</div>
    		</div>
  		</div>		

	  	<div id="savedStudies" style="float:right;padding:4px 8px;"> 		  	<div id="cart" style="cursor:pointer;" onclick="location.href=('/ct2/results'+cartToURL()); showWorking();">
		  	<button class="savedStudiesEnabled" id="open-cart-link" type="button" 
		  		onclick="location.href=('/ct2/results'+cartToURL()); showWorking();"
		  		title="Show previously saved studies.">Saved Studies</button>
		  	</div>
			<button class="savedStudiesDisabled" id="cart-disabled" type="button" disabled
				title="There are no saved studies to show. You can save studies to visit later from the search results page">Saved Studies (0)</button>
		</div>

		<div style="clear:right;text-align:right;padding-top:1ex;padding-right:8px;font-size:small;">
			<a href="https://survey.foreseeresults.com/survey/display?cid=WyHFr2m0PoaGCBUsi00QIQ==&sid=link-ct" target="_blank">Give us feedback</a></div>
		<script type="text/javascript" src="/ct2/html/ct3/js/cart.js?v=b4"></script><noscript></noscript>
  	
<div id="global-nav" class="w3-hide-small">
	<ul class="sf-menu sf-vertical">
			<li class="first"><a href="/ct2/search/index">Find Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Find Studies Menu"></a>
			<ul>
                      <li                  ><a                  href="/ct2/home">New Search</a></li>
                      <li                  ><a         href="/ct2/search/advanced">Advanced Search</a></li>
                      <li                  ><a     href="/ct2/search/browse?brwse=cond_cat">See Studies by Topic</a></li>
                      <li                  ><a             href="/ct2/search/map">See Studies on Map</a></li>
                      <li class="new-group"><a           href="/ct2/help/how-find/index">How to Search</a></li>
                      <li                  ><a href="/ct2/help/how-use-search-results">How to Use Search Results</a></li>
                      <li                  ><a        href="/ct2/help/how-find/find-study-results">How to Find Results of Studies</a></li>
                      <li                  ><a          href="/ct2/help/how-read-study">How to Read a Study Record</a></li>
			</ul>
			</li>
			<li><a href="/ct2/about-studies">About Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="About Studies Menu"></a>
			<ul>
                      <li><a href="/ct2/about-studies/learn">Learn About Studies</a></li>
                      <li><a  href="/ct2/about-studies/other-sites">Other Sites About Studies</a></li>
                      <li><a         href="/ct2/about-studies/glossary">Glossary of Common Site Terms</a></li>
			</ul>
			</li>
			<li><a href="/ct2/manage-recs">Submit Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Submit Studies Menu"></a>
			<ul>
                      <li><a                          href="/ct2/manage-recs/background">Why Should I Register and Submit Results?</a></li>
                      <li><a                                href="/ct2/manage-recs/fdaaa">FDAAA 801 Requirements</a></li>
                      <li class="new-group"><a    href="/ct2/manage-recs/how-apply">How to Apply for an Account</a></li>
                      <li><a                        href="/ct2/manage-recs/how-register">How to Register Your Study</a></li>
                      <li><a                         href="/ct2/manage-recs/how-edit">How to Edit Your Study Record</a></li>
                      <li><a                   href="/ct2/manage-recs/how-report">How to Submit Your Results</a></li>
                      <li class="new-group"><a       href="/ct2/manage-recs/faq">Frequently Asked Questions</a></li>
                      <li                  ><a href="/ct2/manage-recs/resources">Support Materials</a></li>
                      <li                  ><a      href="/ct2/manage-recs/present">Training Materials</a></li>
			</ul>
			</li>
			<li><a href="/ct2/resources">Resources<img src="/ct2/html/ct3/images/pulldown.png" alt="Resources Menu"></a>
			<ul>
                      <li                  ><a    href="/ct2/resources/pubs">Selected Publications</a></li>
                      <li                  ><a       href="/ct2/resources/alert">Clinical Alerts and Advisories</a></li>
                      <li                  ><a     href="/ct2/resources/rss">RSS Feeds</a></li>
                      <li class="new-group"><a href="/ct2/resources/trends">Trends, Charts, and Maps</a></li>
                      <li                  ><a   href="/ct2/resources/download">Downloading Content for Analysis</a></li>
			</ul>
			</li>
			<li class="last"><a href="/ct2/about-site">About Site<img src="/ct2/html/ct3/images/pulldown.png" alt="About Site Menu"></a>
			<ul>
                      <li class="new-group"><a href="/ct2/about-site/background">ClinicalTrials.gov Background</a></li>
                      <li                  ><a    href="/ct2/about-site/results">About the Results Database</a></li>
                      <li                  ><a    href="/ct2/about-site/history">History, Policies, and Laws</a></li>
                      <li                  ><a   href="/ct2/about-site/for-media">Media/Press Resources</a></li>
                      <li class="new-group"><a          href="/ct2/about-site/link-to">Linking to This Site</a></li>
                      <li                  ><a           href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
                      <li                  ><a      href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			</ul>
			</li>
	</ul>
    <div style="clear:both;"></div>
</div>
<div style="clear:both;"></div> 

<div id="utilities">
     
</div>
<div id="breadcrumb">
	<ul class="horz-list">
		<li><a href="/ct2/home">Home</a></li>
				<li class="last">Study Record Detail</li>
	</ul>
</div>


<div id="main-content">


        	<h1 class="solo_record">Remission in Subjects With Crohn's Disease, Open Label Extension (CLASSICII)</h1>
	<div id="trial-info-1" class="floater-50">

     


      
        <div  class="not-recruiting-status" >
      This study has been completed.
          </div>
        
        
      
        




                <div class="info-title">Sponsor:</div>
                <div class="info-text" id="sponsor"> Abbott </div>



                              <div class="info-title">Information provided by:</div>
                <div class="info-text">Abbott</div>
              

            </div>
               <div id="trial-info-2" class="floater-50">
                <div class="info-title">ClinicalTrials.gov Identifier:</div>
                <div class="identifier">NCT01070303</div>
                <div class="info-date">First received: February 16, 2010</div>
                <div class="info-date">Last updated:  April 7, 2011</div>
                <div class="info-date">Last verified:  April 2011 </div>
                <div class="info-date"> <a href="/ct2/archive/NCT01070303"
          title="Historical versions of study NCT01070303 on ClinicalTrials.gov Archive Site - opens in new window"
          onclick="openNewWindow('/ct2/archive/NCT01070303'); return false;">History of Changes</a> </div>
            </div>



<div id="tabs">
        <ul id="tab-links">
			<li id="full-text" ><a href="/ct2/show/study/NCT01070303"  >Full Text View</a></li>
			<li id="tabular"     class="current"> Tabular View       </li>
			<li id="results"   ><a href="/ct2/show/results/NCT01070303">Study Results</a></li>
			<li id="disclaimer"><a href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			<li id="howtoread"><a title="How to Read a Study Record - opens new window"  href="/ct2/help/how-read-study" onclick="openNewWindow('/ct2/help/how-read-study'); return false"
>How to Read a Study Record</a></li>
        </ul>
</div>  <div style="background-color:#f6f6f6;margin-top:3.5ex;padding-bottom:3.5ex;"> </div>




<!-- field list -->
<div class="indent1">
 
  <table class="w3-table data_table tableStyle">
    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Tracking Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">First Received Date&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">February 16, 2010</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Last Updated Date </th>
            <td class="body3 rowBody">April 7, 2011</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Start Date&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">August 2002</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Primary Completion Date </th>
            <td class="body3 rowBody">December 2008 &nbsp; (Final data collection date for primary outcome measure)</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Current Primary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;April 19, 2010)</span></th>
            <td class="body3 rowBody">Number of Participants Achieving Clinical Remission (Crohn&apos;s Disease Activity Index[CDAI] &lt;150 Points) at Week 104 of Study M02-433 (Starting From Week 0 of NCT00055497) (Through 1 Year of Participation in NCT01070303). [&nbsp;Time&nbsp;Frame:&nbsp;Week 104&nbsp;]<div class="indent2" style="margin-top:1ex;">Clinical remission is defined as CDAI score &lt;150. CDAI evaluates 8 Crohn&apos;s&#8722;related variables during a 1&#8722;week assessment period, yielding a composite score &gt;/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. A lower score indicates less severe Crohn&apos;s disease activity.</div></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Original Primary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;February 16, 2010)</span></th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Evaluation of Adverse Events [&nbsp;Time&nbsp;Frame:&nbsp;up to Wk 260&nbsp;]</li>
<li style="margin:1ex 0.5ex">Clinically Significant Laboratory Changes per Investigator&apos;s Discretion [&nbsp;Time&nbsp;Frame:&nbsp;up to Wk 260&nbsp;]</li>
<li style="margin:1ex 0.5ex">Clinically Significant Physical Exam Changes per Investigator&apos;s Discretion [&nbsp;Time&nbsp;Frame:&nbsp;up to Wk 260&nbsp;]</li>
<li style="margin:1ex 0.5ex">Clinically Significant Vital Sign Changes per Investigator&apos;s Discretion [&nbsp;Time&nbsp;Frame:&nbsp;up to Wk 260&nbsp;]</li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Change History </th>
            <td class="body3 rowBody"><a href="/ct2/archive/NCT01070303" onclick="openNewWindow('/ct2/archive/NCT01070303'); return false;">Complete list of historical versions of study NCT01070303 on ClinicalTrials.gov Archive Site</a></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Current Secondary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;April 19, 2010)</span></th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Number of Participants Achieving Clinical Remission (CDAI &lt; 150 Points) at Week 152 (Through 2 Years of Participation in NCT01070303). [&nbsp;Time&nbsp;Frame:&nbsp;Week 152&nbsp;]<div class="indent2" style="margin-top:1ex;">Clinical remission is defined as CDAI score &lt;150. CDAI evaluates 8 Crohn&apos;s&#8722;related variables during a 1&#8722;week assessment period, yielding a composite score &gt;/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. A lower score indicates less severe Crohn&apos;s disease activity.</div></li>
<li style="margin:1ex 0.5ex">Number of Participants Achieving Clinical Remission (CDAI &lt; 150 Points) at Week 212 (Through 3 Years of Participation in NCT01070303). [&nbsp;Time&nbsp;Frame:&nbsp;Week 212&nbsp;]<div class="indent2" style="margin-top:1ex;">Clinical remission is defined as CDAI score &lt;150. CDAI evaluates 8 Crohn&apos;s&#8722;related variables during a 1&#8722;week assessment period, yielding a composite score &gt;/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. A lower score indicates less severe Crohn&apos;s disease activity.</div></li>
<li style="margin:1ex 0.5ex">Number of Participants Achieving Clinical Remission (CDAI &lt; 150 Points) at Week 260 (4 Years of Participation in NCT01070303). [&nbsp;Time&nbsp;Frame:&nbsp;Week 260&nbsp;]<div class="indent2" style="margin-top:1ex;">Clinical remission is defined as CDAI score &lt;150. CDAI evaluates 8 Crohn&apos;s&#8722;related variables during a 1&#8722;week assessment period, yielding a composite score &gt;/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. A lower score indicates less severe Crohn&apos;s disease activity.</div></li>
<li style="margin:1ex 0.5ex">Number of Participants Achieving CR-100 at Week 104 (1 Year of Participation in NCT01070303) [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline of lead-in study to Week 104&nbsp;]<div class="indent2" style="margin-top:1ex;">A CR-100 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 100 or more points, indicating significant improvement in disease severity. CDAI evaluates 8 Crohn&apos;s&#8722;related variables during a 1&#8722;week assessment period, yielding a composite score &gt;/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn&apos;s disease activity.</div></li>
<li style="margin:1ex 0.5ex">Number of Participants Achieving CR-100 at Week 152 (2 Years of Participation in NCT01070303) [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline of lead-in study to Week 152&nbsp;]<div class="indent2" style="margin-top:1ex;">A CR-100 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 100 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn&apos;s&#8722;related variables during a 1&#8722;week assessment period, yielding a composite score &gt;/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn&apos;s disease activity.</div></li>
<li style="margin:1ex 0.5ex">Number of Participants Achieving CR-100 at Week 212 (3 Years of Participation in NCT01070303) [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline of lead-in study to Week 212&nbsp;]<div class="indent2" style="margin-top:1ex;">A CR-100 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 100 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn&apos;s&#8722;related variables during a 1&#8722;week assessment period, yielding a composite score &gt;/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn&apos;s disease activity.</div></li>
<li style="margin:1ex 0.5ex">Number of Participants Achieving CR-100 at Week 260 (4 Years of Participation in NCT01070303) [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline of lead-in study to Week 260&nbsp;]<div class="indent2" style="margin-top:1ex;">A CR-100 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 100 or more points, indicating significant improvement in disease severity. CDAI evaluates 8 Crohn&apos;s&#8722;related variables during a 1&#8722;week assessment period, yielding a composite score &gt;/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn&apos;s disease activity.</div></li>
<li style="margin:1ex 0.5ex">Number of Participants Achieving CR-70 at Week 104 (1 Year of Participation in NCT01070303) [&nbsp;Time&nbsp;Frame:&nbsp;Week 104&nbsp;]<div class="indent2" style="margin-top:1ex;">A CR-70 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 70 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn&apos;s&#8722;related variables during a 1&#8722;week assessment period, yielding a composite score &gt;/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn&apos;s disease activity.</div></li>
<li style="margin:1ex 0.5ex">Number of Participants Achieving CR-70 at Week 152 (2 Years of Participation in NCT01070303) [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline of lead-in Study to Week 152&nbsp;]<div class="indent2" style="margin-top:1ex;">A CR-70 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 70 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn&apos;s&#8722;related variables during a 1&#8722;week assessment period, yielding a composite score &gt;/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn&apos;s disease activity.</div></li>
<li style="margin:1ex 0.5ex">Number of Participants Achieving CR-70 at Week 212 (3 Years of Participation in NCT01070303) [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline of lead-in study to Week 212&nbsp;]<div class="indent2" style="margin-top:1ex;">CR-70 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 70 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn&apos;s&#8722;related variables during a 1&#8722;week assessment period, yielding a composite score &gt;/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn&apos;s disease activity.</div></li>
<li style="margin:1ex 0.5ex">Number of Participants Achieving CR-70 at Week 260 (4 Years of Participation in NCT01070303) [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline of lead-in study to Week 260&nbsp;]<div class="indent2" style="margin-top:1ex;">A CR-70 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 70 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn&apos;s&#8722;related variables during a 1&#8722;week assessment period, yielding a composite score &gt;/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn&apos;s disease activity.</div></li>
<li style="margin:1ex 0.5ex">Number of Participants Achieving Steroid-free Clinical Remission at Week 104 (1 Year of Participation in NCT01070303) [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline of lead-in study to Week 104&nbsp;]<div class="indent2" style="margin-top:1ex;">Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free remission was achieved if the participant stopped taking corticosteroids before the visit and had a CDAI score &lt; 150 points at that visit.</div></li>
<li style="margin:1ex 0.5ex">Number of Achieving Steroid-free Clinical Remission at Week 152 (2 Years of Participation in NCT01070303) [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline of lead-in study to Week 152&nbsp;]<div class="indent2" style="margin-top:1ex;">Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free remission was achieved if the participant stopped taking corticosteroids before the visit and had a CDAI score &lt; 150 points at that visit.</div></li>
<li style="margin:1ex 0.5ex">Number of Participants Achieving Steroid-free Clinical Remission at Week 212 (3 Years of Participation in NCT01070303) [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline of lead-in study to Week 212&nbsp;]<div class="indent2" style="margin-top:1ex;">Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free remission was achieved if the participant stopped taking corticosteroids before the visit and had a CDAI score &lt; 150 points at that visit.</div></li>
<li style="margin:1ex 0.5ex">Number of Participants Achieving Steroid-free Clinical Remission at Week 260 (4 Years of Participation in NCT01070303) [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline of lead-in study to Week 260&nbsp;]<div class="indent2" style="margin-top:1ex;">Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free remission was achieved if the participant stopped taking corticosteroids before the visit and had a CDAI score &lt; 150 points at that visit.</div></li>
<li style="margin:1ex 0.5ex">Number of Participants Achieving Steroid-free CR-100 at Week 104 (1 Year of Participation in NCT01070303) [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline of lead-in study to Week 104&nbsp;]<div class="indent2" style="margin-top:1ex;">Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free CR-100 was achieved if the participant stopped taking steroids before the visit and had a decrease from Baseline in CDAI score of 100 or more points at that visit.</div></li>
<li style="margin:1ex 0.5ex">Number of Participants Achieving Steroid-free CR-100 at Week 152 (2 Years of Participation in NCT01070303) [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline of lead-in study to Week 152&nbsp;]<div class="indent2" style="margin-top:1ex;">Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free CR-100 was achieved if the participant stopped taking steroids before the visit and had a decrease from Baseline in CDAI score of 100 or more points at that visit.</div></li>
<li style="margin:1ex 0.5ex">Number of Participants Achieving Steroid-free CR-100 at Week 212 (3 Years of Participation in NCT01070303) [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline of lead-in study to Week 212&nbsp;]<div class="indent2" style="margin-top:1ex;">Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free CR-100 was achieved if the participant stopped taking steroids before the visit and had a decrease from Baseline in CDAI score of 100 or more points at that visit.</div></li>
<li style="margin:1ex 0.5ex">Number of Participants Achieving Steroid-free CR-100 at Week 260 (4 Years of Participation in NCT01070303) [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline of lead-in study to Week 260&nbsp;]<div class="indent2" style="margin-top:1ex;">Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free CR-100 was achieved if the participant stopped taking steroids before the visit and had a decrease from Baseline in CDAI score of 100 or more points at that visit.</div></li>
<li style="margin:1ex 0.5ex">Changes in Inflammatory Bowel Disease Questionnaire (IBDQ) Scores [&nbsp;Time&nbsp;Frame:&nbsp;Change from Baseline of lead-in study at Weeks 104, 152, 200, and 248&nbsp;]<div class="indent2" style="margin-top:1ex;">IBDQ is a validated disease&#8722;specific instrument that assesses the impact of IBD on patient quality of life during a 2&#8722;week recall period. It has 32 questions about bowel function and related symptoms, and their social and emotional impact. For each question, participants selected 1 of 7 responses, where 1=poor quality of life (e.g., feeling of fatigue &quot;all of the time&quot;) and 7=good quality on the item (e.g., feeling of fatigue &quot;none of the time&quot;). IBDQ scores range from 32 to 224. Higher scores indicate better quality of life, and increases in IBDQ indicate improved overall quality of life.</div></li>
<li style="margin:1ex 0.5ex">Number of Participants Achieving Fistula Remission at Week 104 (1 Year of Participation in NCT01070303) [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline of lead-in study to Week 104&nbsp;]<div class="indent2" style="margin-top:1ex;">A count of the number of cutaneous fistulas draining upon gentle compression was performed at Baseline of the lead-in study (NCT00055523) and at study visits. Among participants with draining fistulas at Baseline of NCT00055523, a participant was considered to have achieved fistula remission at a study visit if the participant had no draining cutaneous fistulas at that visit.</div></li>
<li style="margin:1ex 0.5ex">Number of Participants Achieving Fistula Remission at Week 152 (2 Years of Participation in NCT01070303) [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline of lead-in study to Week 152&nbsp;]<div class="indent2" style="margin-top:1ex;">A count of the number of cutaneous fistulas draining upon gentle compression was performed at Baseline of the lead-in study (NCT00055523) and at study visits. Among participants with draining fistulas at Baseline of NCT00055523, a participant was considered to have achieved fistula remission at a study visit if the participant had no draining cutaneous fistulas at that visit.</div></li>
<li style="margin:1ex 0.5ex">Number of Participants Achieving Fistula Remission at Week 212 (3 Years of Participation in NCT01070303) [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline of lead-in study to Week 212&nbsp;]<div class="indent2" style="margin-top:1ex;">A count of the number of cutaneous fistulas draining upon gentle compression was performed at Baseline of the lead-in study (NCT00055523) and at study visits. Among participants with draining fistulas at Baseline of NCT00055523, a participant was considered to have achieved fistula remission at a study visit if the participant had no draining cutaneous fistulas at that visit.</div></li>
<li style="margin:1ex 0.5ex">Number of Participants Achieving Fistula Remission at Week 260 (Years of Participation in NCT01070303) [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline of lead-in study to Week 260&nbsp;]<div class="indent2" style="margin-top:1ex;">A count of the number of cutaneous fistulas draining upon gentle compression was performed at Baseline of the lead-in study (NCT00055523) and at study visits. Among participants with draining fistulas at Baseline of NCT00055523, a participant was considered to have achieved fistula remission at a study visit if the participant had no draining cutaneous fistulas at that visit.</div></li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Original Secondary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;February 16, 2010)</span></th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Percentage of Subjects Achieving Clinical Remission [&nbsp;Time&nbsp;Frame:&nbsp;Week 260&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Subjects Achieving CR-70 [&nbsp;Time&nbsp;Frame:&nbsp;: Week 260&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Subjects Achieving CR-100 [&nbsp;Time&nbsp;Frame:&nbsp;Week 260&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Subjects Achieving Steroid-free Clinical Remission [&nbsp;Time&nbsp;Frame:&nbsp;Week 260&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Subjects Achieving Steroid-free CR-100 [&nbsp;Time&nbsp;Frame:&nbsp;Week 260&nbsp;]</li>
<li style="margin:1ex 0.5ex">Changes in Inflammatory Bowel Disease Questionnaire (IBDQ) [&nbsp;Time&nbsp;Frame:&nbsp;Week 248&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Subjects With Fistula Remission [&nbsp;Time&nbsp;Frame:&nbsp;Week 260&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Subjects With Infection [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 of Study M02-403 through Week 260 of Study M02-433&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Subjects With Serious Infection [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 of Study M02-403 through Week 260 of Study M02-433&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Subjects With Lymphoma [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 of Study M02-403 through Week 260 of Study M02-433&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Subjects With Malignancy [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 of Study M02-403 through Week 260 of Study M02-433&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Subjects With Nonmelanoma Skin Cancer [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 of Study M02-403 through Week 260 of Study M02-433&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Subjects With Malignancy (Excluding Nonmelanoma Skin Cancer and Lymphoma) [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 of Study M02-403 through Week 260 of Study M02-433&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Subjects With Malignancy (Including Lymphoma, Excluding Nonmelanoma Skin Cancer) [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 of Study M02-403 through Week 260 of Study M02-433&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Subjects With Injection Site Reaction-related Adverse Events [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 of Study M02-403 through Week 260 of Study M02-433&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Subjects With Opportunistic Infection (Excluding Tuberculosis) [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 of Study M02-403 through Week 260 of Study M02-433&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Subjects With Congestive Heart Failure [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 of Study M02-403 through Week 260 of Study M02-433&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Subjects With Hepatic-related Adverse Events [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 of Study M02-403 through Week 260 of Study M02-433&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Subjects With Demyelinating Disease [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 of Study M02-403 through Week 260 of Study M02-433&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Subjects With Allergic Reaction-related Adverse Events [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 of Study M02-403 through Week 260 of Study M02-433&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Subjects With Lupus-like Syndrome [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 of Study M02-403 through Week 260 of Study M02-433&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Subjects With Hematologic-related Adverse Events [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 of Study M02-403 through Week 260 of Study M02-433&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Subjects With Fatal Adverse Events [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 of Study M02-403 through Week 260 of Study M02-433&nbsp;]</li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Current Other Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Original Other Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
    
    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Descriptive Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Brief Title&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Remission in Subjects With Crohn's Disease, Open Label Extension</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Official Title&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Maintenance of Clinical Remission in Subjects With Crohn's Disease, Open Label Extension</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Brief Summary </th>
            <td class="body3 rowBody">The objectives were: (1) To demonstrate the efficacy of adalimumab in the long-term maintenance of clinical remission in participants with Crohn's disease; and (2) To delineate the long-term safety of adalimumab when administered to participants with Crohn's disease.</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Detailed Description </th>
            <td class="body3 rowBody"><p style="margin-top:1ex; margin-bottom:1ex;">Study M02-433 was designed to evaluate the efficacy and safety of adalimumab in the maintenance of clinical remission in patients with Crohn's disease (CD). The study consisted of 2 phases: 1. a 1-year phase (Week 0 to Week 56) (NCT00055497) that consisted of a randomized, double-blind, placebo-controlled portion with a concomitant open label (OL) portion, and 2. a long-term open-label extension (OLE) phase (NCT01070303) that lasted 264 additional weeks (Week 56 to Week 320).</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">Participants who completed the lead-in study NCT00055523, were eligible to participate in the rollover study, NCT00055497. 176 participants were documented as having completed Year 1 (NCT00055497); however, 177 participants were still receiving study drug and were evaluated at Week 56 of NCT00055497; these participants are included in the OLE data (NCT01070303).</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">At Week 4 of NCT00055497, participants who demonstrated clinical remission (defined as a Crohn's Disease Activity Index [CDAI] score &lt;150 points) at Baseline of NCT00055497 and who remained in clinical remission at Week 4 (&quot;Remitters&quot;) were randomized to receive 1 of 3 blinded treatments: placebo, adalimumab 40 mg every other week (eow), or adalimumab 40 mg every week (ew). Participants who did not demonstrate clinical remission at Baseline of NCT00055497 or who were no longer in clinical remission at Week 4 of NCT00055497 (&quot;Non-remitters&quot;) were assigned to receive OL adalimumab 40 mg eow. All study drug (placebo and active) was administered by subcutaneous (SC) injection.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">At any time during Study NCT00055497, a participant receiving blinded study drug who developed a disease flare could be switched to OL adalimumab 40 mg eow. A participant receiving OL adalimumab 40 mg SC eow who developed a flare or was a non-responders could have had his/her dose increased to 40 mg SC ew.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">After 1 year (Week 56 of NCT00055497), patients who were still participating could continue in the OLE phase (NCT01070303). Participants who were receiving blinded study drug were switched to OL adalimumab 40 mg SC eow, and participants who were receiving OL study drug continued on their previous OL adalimumab dose (adalimumab 40 mg SC eow or ew).</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">Data are summarized for Remitters and Non-remitters, with the exception of data for primary reason for noncompletion. Summaries of primary reason for noncompletion were available only for all participants, not for Remitters and Non-remitters. Data are reported for Weeks 104, 152, 212, and 260 of Study M02-433, starting from Week 0 of NCT00055497; these weeks correspond to 1, 2, 3, and 4 years of participation in NCT01070303. Change from Baseline results (clinical response 70, clinical response 100, Inflammatory Bowel Disease Questionnaire, and fistula remission) are calculated from Baseline of the lead-in study (NCT00055523). Results on each assessment at each measurement time point are presented as individual outcome measures because different numbers of participants were evaluated at each time point (as observed analysis).</p></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Type&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Interventional</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Phase </th>
            <td class="body3 rowBody">Phase 3</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Design&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Intervention Model: Single Group Assignment<br/>Masking: Open Label<br/>Primary Purpose: Treatment</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Condition&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Crohn's Disease</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Intervention&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Biological: Adalimumab 40 mg eow or ew
<div class="indent2" style="margin-top:0.5ex">Adalimumab 40 mg by subcutaneous injection every other week or every week</div>
<div class="indent2" style="margin-top:0.5ex">Other Names:<ul style="margin-top:0.5ex">
<li>Adalimumab</li>
<li>Humira</li>
</ul>
</div></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Arms </th>
            <td class="body3 rowBody">Experimental: Adalimumab 40 mg every other week or every week
<div class="indent2" style="margin-top:0.5ex">Intervention: Biological: Adalimumab 40 mg eow or ew</div></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Publications * </th>
            <td class="missing_color">Not Provided</td>
          </tr>
    
    <tr>
      <td class="header3" style="padding-left:2em" colspan="2">
        <br/>
        * &nbsp; Includes publications given by the data provider as well as publications
        identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
      </td>
    </tr>

    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Recruitment Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Recruitment Status&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Completed</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Enrollment&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">177</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Completion Date </th>
            <td class="body3 rowBody">December 2008</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Primary Completion Date </th>
            <td class="body3 rowBody">December 2008 &nbsp; (Final data collection date for primary outcome measure)</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Eligibility Criteria&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><p style="margin-top:1ex; margin-bottom:1ex;">Inclusion Criteria:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Participant had completed the Year 1 of Study M02-433 (NCT00055497)</li>
    <li style="margin-top:0.7ex;">Diagnosis of Crohn's disease</li>
    <li style="margin-top:0.7ex;">Willing and able to give informed consent</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">Exclusion Criteria:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Diagnosis of ulcerative colitis</li>
    <li style="margin-top:0.7ex;">Pregnancy or breastfeeding</li>
    <li style="margin-top:0.7ex;">Previous use of infliximab or other anti-TNF (tumor necrosing factor) antagonists</li>
    <li style="margin-top:0.7ex;">Previous history of active tuberculosis or listeria infection</li>
    <li style="margin-top:0.7ex;">Previous history of cancer other than successfully treated skin cancer</li>
  </ul></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Sex/Gender </th>
            <td class="body3 rowBody"><table class="layout_table" cellpadding="0" cellspacing="0" style="border:none;">
  <tr valign="top">
   <td style="padding:0px; margin:0ex; border:none;" nowrap>Sexes Eligible for Study:</td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">All</td>
  </tr>
</table>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Ages </th>
            <td class="body3 rowBody">18 Years to 75 Years &nbsp; (Adult, Senior)</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Accepts Healthy Volunteers </th>
            <td class="body3 rowBody">No</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Contacts&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><i style="color:#777777">Contact information is only displayed when the study is recruiting subjects</i></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Listed Location Countries&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">United States</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Removed Location Countries </th>
            <td class="body3"> &nbsp; </td>
          </tr>
    
    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Administrative Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">NCT Number&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">NCT01070303</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Other Study ID Numbers&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">M02-433 Open Label</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Has Data Monitoring Committee </th>
            <td class="body3 rowBody">No</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">U.S. FDA-regulated Product </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">IPD Sharing Statement </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Responsible Party </th>
            <td class="body3 rowBody">Anne Camez, Medical Director, Abbott</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Sponsor&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Abbott</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Collaborators&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Investigators&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><table class="layout_table" cellpadding="0" cellspacing="0" style="border:none;">
  <tr valign="top">
   <td style="padding:0px; margin:0ex; border:none;" nowrap>Study Director:</td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">Anne Camez, MD</td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">Abbott</td>
  </tr>
</table>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">PRS Account </th>
            <td class="body3 rowBody">Abbott</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Verification Date </th>
            <td class="body3 rowBody">April 2011</td>
          </tr>
    
    <tr>
      <td class="header3" style="padding-left:2em" colspan="2">
        <br/>
        <sup style="color:blue"> ICMJE </sup>&nbsp; &nbsp; Data element required by the
        <a href="http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html">
        International Committee of Medical Journal Editors</a> and the
        <a href="http://www.who.int/ictrp/network/trds/en/index.html">World Health Organization ICTRP</a>
      </td>
    </tr>

  </table>
</div>


<div id="to-top"><a href="#wrapper">To Top</a></div>

	<div style="clear:both;"></div>
</div> 

      <div id="for-footer">
        <ul class="horz-list">
            <li style="border-left:0;"><a    href="/ct2/help/for-patient">For Patients and Families</a></li>
            <li><a href="/ct2/help/for-researcher">For Researchers</a></li>
            <li><a     href="/ct2/help/for-manager">For Study Record Managers</a></li>
        </ul>
    </div>

<div id="footer-menu">
    <ul class="horz-list">
		<li><a href="/ct2/home" style="white-space:nowrap">Home</a></li>
		<li><a     href="/ct2/resources/rss" style="white-space:nowrap">RSS Feeds</a></li>
		<li><a         href="/ct2/sitemap" style="white-space:nowrap">Site Map</a></li>
		<li><a       href="/ct2/about-site/terms-conditions" style="white-space:nowrap">Terms and Conditions</a></li>
		<li><a href="/ct2/about-site/disclaimer" style="white-space:nowrap">Disclaimer</a></li>
		<li><a        href="https://support.nlm.nih.gov/ics/support/KBList.asp?folderID=146?style=classic&amp;deptID=28054&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Frecord%2FNCT01070303" style="white-space:nowrap" onclick="openNewWindow('https://support.nlm.nih.gov/ics/support/KBList.asp?folderID=146?style=classic&amp;deptID=28054&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Frecord%2FNCT01070303'); return false">Customer Support</a></li>
	</ul>
</div>

</div>  
<div id="fine-print">
	<ul class="horz-list">
		<li                  ><a title="NLM copyright information - opens new window"  href="https://www.nlm.nih.gov/copyright.html" onclick="openNewWindow('https://www.nlm.nih.gov/copyright.html'); return false"
>Copyright</a></li>
		<li                  ><a title="NLM privacy policy - opens new window"  href="https://www.nlm.nih.gov/privacy.html" onclick="openNewWindow('https://www.nlm.nih.gov/privacy.html'); return false"
>Privacy</a></li>
		<li                  ><a href="/ct2/accessibility" title="NLM Accessibility">Accessibility</a></li>
		<li                  ><a title="NLM viewers and players - opens new window"  href="https://www.nlm.nih.gov/plugins.html" onclick="openNewWindow('https://www.nlm.nih.gov/plugins.html'); return false"
>Viewers and Players</a></li>
		<li                  ><a title="NIH Freedom of Information Act office - opens new window"  href="https://www.nih.gov/icd/od/foia/index.htm" onclick="openNewWindow('https://www.nih.gov/icd/od/foia/index.htm'); return false"
>Freedom of Information Act</a></li>
		<li class="last-item"><a title="USA.gov - opens new window"  href="https://www.usa.gov/" onclick="openNewWindow('https://www.usa.gov/'); return false"
>USA.gov</a></li>
	</ul>
    <ul class="horz-list">
       <li><a title="U.S. National Library of Medicine - opens new window"  href="https://www.nlm.nih.gov/" onclick="openNewWindow('https://www.nlm.nih.gov/'); return false"
>U.S. National Library of Medicine</a></li>
       <li><a title="U.S. National Institutes of Health - opens new window"  href="https://www.nih.gov/" onclick="openNewWindow('https://www.nih.gov/'); return false"
>U.S. National Institutes of Health</a></li>
       <li class="last-item"><a title="U.S. Department of Health and Human Services - opens new window"  href="https://www.hhs.gov/" onclick="openNewWindow('https://www.hhs.gov/'); return false"
>
            U.S. Department of Health and Human Services</a></li>
    </ul>
</div>

    <script type="text/javascript" src="/ct2/html/ct3/js/instrumentNCBIBaseJS.min.js"></script><noscript></noscript>

</body>
</html>
